Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

A buyer for Sandoz, already?

Posted 24 November 2021 PM

Novartis may be on the verge of separating itself from its generics arm, Sandoz, with investors reportedly considering a joint offer.

Swedish-based investment group EQT and the Struengmann family of Germany, who were early backers of BioNtech, are considering a joint move to purchase the generics division, German daily newspaper Handelsblatt reported, citing unnamed sources.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.